Clinical trial
Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of…
NCT00241111 · Novartis Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00241111 |
|---|---|
| Title | Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis |
| Official title | Assessment of the Efficacy, Tolerability and Pharmaco-economic Impact of Zoledronic Acid Treatment in Prostate Cancer With Bone Metastasis |
| Lead sponsor | Novartis Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 4 |
| Study type | Interventional |
| Conditions | Prostate Cancer With Bone Metastasis |
| Intervention type | Drug |
| Interventions | zoledronic acid |
| Enrollment | 148 |
| Start date | Sep 1, 2003 |
| Primary completion | Jan 1, 2006 |
| First posted | Oct 18, 2005 |
| Last update posted | Mar 6, 2017 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: